BR112023017454A2 - Derivados de benzo[c][2,6]naftiridina, composições e usos terapêuticos dos mesmos - Google Patents
Derivados de benzo[c][2,6]naftiridina, composições e usos terapêuticos dos mesmosInfo
- Publication number
- BR112023017454A2 BR112023017454A2 BR112023017454A BR112023017454A BR112023017454A2 BR 112023017454 A2 BR112023017454 A2 BR 112023017454A2 BR 112023017454 A BR112023017454 A BR 112023017454A BR 112023017454 A BR112023017454 A BR 112023017454A BR 112023017454 A2 BR112023017454 A2 BR 112023017454A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compositions
- benzo
- ck2a
- therapeutic uses
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102000052052 Casein Kinase II Human genes 0.000 abstract 1
- 108010010919 Casein Kinase II Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- KPAPDFOTQNAQCH-UHFFFAOYSA-N benzo[c][2,6]naphthyridine Chemical class C1=NC=C2C3=CC=CC=C3N=CC2=C1 KPAPDFOTQNAQCH-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
derivados de benzo[c][2,6]naftiridina, composições e usos terapêuticos dos mesmos. são providos compostos da fórmula i e sais, hidratos e solvatos dos mesmos: em que r1, q, ra, rb, rc, rd e re são, cada um, conforme definido no relatório descritivo. os compostos são inibidores da caseína quinase 2 alfa (ck2a) e são úteis para o tratamento e/ou prevenção de doenças e condições nas quais a atividade da ck2a está implicada, como, por exemplo, mas não limitados ao tratamento e/ou prevenção de distúrbios proliferativos (por exemplo, câncer), infecções virais, inflamação, diabetes, distúrbios vasculares e isquêmicos, neurodegeneração e a regulação do ritmo circadiano. a presente invenção também se refere a composições farmacêuticas compreendendo os compostos aqui definidos, a processos para sintetizar esses compostos e ao seu uso para o tratamento de doenças e/ou condições nas quais a atividade de ck2a está implicada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2102895.6A GB202102895D0 (en) | 2021-03-01 | 2021-03-01 | Novel compounds, compositions and therapeutic uses thereof |
| PCT/GB2022/050536 WO2022185041A1 (en) | 2021-03-01 | 2022-02-28 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023017454A2 true BR112023017454A2 (pt) | 2023-11-07 |
Family
ID=75377345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023017454A BR112023017454A2 (pt) | 2021-03-01 | 2022-02-28 | Derivados de benzo[c][2,6]naftiridina, composições e usos terapêuticos dos mesmos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11866436B2 (pt) |
| EP (1) | EP4301752A1 (pt) |
| JP (1) | JP2024508547A (pt) |
| KR (1) | KR20230154209A (pt) |
| CN (1) | CN117295736A (pt) |
| AU (1) | AU2022229939A1 (pt) |
| BR (1) | BR112023017454A2 (pt) |
| CA (1) | CA3209573A1 (pt) |
| GB (1) | GB202102895D0 (pt) |
| IL (1) | IL305360A (pt) |
| MX (1) | MX2023010141A (pt) |
| WO (1) | WO2022185041A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202213162D0 (en) * | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
| GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213167D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213166D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| DK1553097T3 (da) | 1999-02-10 | 2010-12-13 | Astrazeneca Ab | Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil |
| US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
| MX2009002298A (es) * | 2006-09-01 | 2009-06-04 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteina quinasa y de parp. |
| JP2010520303A (ja) | 2007-03-08 | 2010-06-10 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| AU2009219154A1 (en) * | 2008-02-29 | 2009-09-03 | Cylene Pharmaceuticals, Inc. | Protein kinase modulators |
| MX2012003997A (es) * | 2009-10-02 | 2012-07-25 | Cylene Pharmaceuticals Inc | Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2. |
| NZ703989A (en) | 2012-09-07 | 2017-04-28 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
-
2021
- 2021-03-01 GB GBGB2102895.6A patent/GB202102895D0/en not_active Ceased
-
2022
- 2022-02-28 WO PCT/GB2022/050536 patent/WO2022185041A1/en active Application Filing
- 2022-02-28 JP JP2023553683A patent/JP2024508547A/ja active Pending
- 2022-02-28 AU AU2022229939A patent/AU2022229939A1/en active Pending
- 2022-02-28 EP EP22708593.3A patent/EP4301752A1/en active Pending
- 2022-02-28 IL IL305360A patent/IL305360A/en unknown
- 2022-02-28 KR KR1020237033043A patent/KR20230154209A/ko unknown
- 2022-02-28 MX MX2023010141A patent/MX2023010141A/es unknown
- 2022-02-28 CN CN202280032445.0A patent/CN117295736A/zh active Pending
- 2022-02-28 BR BR112023017454A patent/BR112023017454A2/pt unknown
- 2022-02-28 CA CA3209573A patent/CA3209573A1/en active Pending
-
2023
- 2023-04-14 US US18/134,894 patent/US11866436B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023010141A (es) | 2023-09-29 |
| JP2024508547A (ja) | 2024-02-27 |
| EP4301752A1 (en) | 2024-01-10 |
| IL305360A (en) | 2023-10-01 |
| CN117295736A (zh) | 2023-12-26 |
| AU2022229939A1 (en) | 2023-09-07 |
| US11866436B2 (en) | 2024-01-09 |
| CA3209573A1 (en) | 2022-09-09 |
| WO2022185041A1 (en) | 2022-09-09 |
| GB202102895D0 (en) | 2021-04-14 |
| US20230250097A1 (en) | 2023-08-10 |
| KR20230154209A (ko) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023017454A2 (pt) | Derivados de benzo[c][2,6]naftiridina, composições e usos terapêuticos dos mesmos | |
| BR112018071097A2 (pt) | compostos heterocíclicos como inibidores de ret cinase | |
| SV2010003491A (es) | 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| BR112021022778A2 (pt) | Compostos e métodos para o tratamento de covid-19 | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112017012402A2 (pt) | derivados de 2,4-dioxo-quinazolina-6-sulfonamida como inibidores de parg | |
| BR112021017831A2 (pt) | Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose | |
| PH12019500615A1 (en) | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA and GAMMA | |
| BR112022009805A2 (pt) | Derivados de piridopirimidinona como antagonistas de ahr | |
| BR112014006223A8 (pt) | 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
| BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
| BR112022010181A2 (pt) | Composto tri-heterocíclico como inibidor de jak e uso do mesmo | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| BR112022022437A2 (pt) | Antagonistas do receptor a2a de adenosina | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| BR112022025946A2 (pt) | Composto, composição farmacêutica e método de tratamento de uma doença | |
| EP2211849A2 (en) | Dexanabinol with inhibitors of braf or mek for the treatment of melanoma | |
| BR112021026754A2 (pt) | Composto, métodos para tratar um paciente com uma doença ou transtorno suscetível, para inibir janus quinase e para tratar uma ou mais doenças ou transtornos de inflamação, disfunção autoimune e câncer, composição, combinação, e, uso de um composto | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| BR112023020538A2 (pt) | Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer | |
| AR102208A1 (es) | Compuestos de isotiazolo tiazina inhibidores de bace1 |